NASDAQ:RLAY

Relay Therapeutics Competitors

$33.63
-1.72 (-4.87 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.33
Now: $33.63
$36.12
50-Day Range
$32.52
MA: $38.35
$44.02
52-Week Range
$31.31
Now: $33.63
$64.37
Volume844,000 shs
Average Volume781,312 shs
Market Capitalization$3.04 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Relay Therapeutics (NASDAQ:RLAY) Vs. QGEN, RGEN, NBIX, CRSP, XLRN, and FATE

Should you be buying RLAY stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Relay Therapeutics, including QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), and Fate Therapeutics (FATE).

Relay Therapeutics (NASDAQ:RLAY) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Relay Therapeutics and QIAGEN's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
QIAGEN$1.53 billion7.66$-41,460,000.00$1.4335.87

Relay Therapeutics has higher earnings, but lower revenue than QIAGEN.

Profitability

This table compares Relay Therapeutics and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
QIAGEN11.18%17.51%8.44%

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 43.6% of QIAGEN shares are held by institutional investors. 9.0% of QIAGEN shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for Relay Therapeutics and QIAGEN, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
QIAGEN05902.64

Relay Therapeutics currently has a consensus price target of $57.40, suggesting a potential upside of 70.68%. QIAGEN has a consensus price target of $60.76, suggesting a potential upside of 18.46%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Relay Therapeutics is more favorable than QIAGEN.

Summary

QIAGEN beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

Repligen (NASDAQ:RGEN) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Repligen and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million41.77$21.41 million$1.07192.62
Relay TherapeuticsN/AN/AN/AN/AN/A

Repligen has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Repligen and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen13.40%6.58%5.00%
Relay TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

84.3% of Repligen shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 1.7% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Repligen and Relay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00503.00
Relay Therapeutics01502.83

Repligen currently has a consensus target price of $204.75, suggesting a potential downside of 0.66%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Repligen.

Summary

Repligen beats Relay Therapeutics on 6 of the 8 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Neurocrine Biosciences and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.13$37.01 million$0.39239.36
Relay TherapeuticsN/AN/AN/AN/AN/A

Neurocrine Biosciences has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares Neurocrine Biosciences and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Relay TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Neurocrine Biosciences and Relay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081202.60
Relay Therapeutics01502.83

Neurocrine Biosciences currently has a consensus target price of $129.2222, suggesting a potential upside of 38.43%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Neurocrine Biosciences.

Summary

Neurocrine Biosciences beats Relay Therapeutics on 6 of the 9 factors compared between the two stocks.

CRISPR Therapeutics (NASDAQ:CRSP) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares CRISPR Therapeutics and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million30.15$66.86 million$1.1798.92
Relay TherapeuticsN/AN/AN/AN/AN/A

CRISPR Therapeutics has higher revenue and earnings than Relay Therapeutics.

Profitability

This table compares CRISPR Therapeutics and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
Relay TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

66.4% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 17.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for CRISPR Therapeutics and Relay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241202.56
Relay Therapeutics01502.83

CRISPR Therapeutics currently has a consensus target price of $158.80, suggesting a potential upside of 37.20%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than CRISPR Therapeutics.

Summary

Relay Therapeutics beats CRISPR Therapeutics on 6 of the 9 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and Relay Therapeutics (NASDAQ:RLAY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and target prices for Acceleron Pharma and Relay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma031012.86
Relay Therapeutics01502.83

Acceleron Pharma currently has a consensus target price of $148.2143, suggesting a potential upside of 16.84%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Acceleron Pharma.

Valuation & Earnings

This table compares Acceleron Pharma and Relay Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million103.81$-124,860,000.00($2.38)-53.30
Relay TherapeuticsN/AN/AN/AN/AN/A

Relay Therapeutics has lower revenue, but higher earnings than Acceleron Pharma.

Profitability

This table compares Acceleron Pharma and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-157.84%-31.62%-28.11%
Relay TherapeuticsN/AN/AN/A

Institutional and Insider Ownership

79.8% of Acceleron Pharma shares are held by institutional investors. Comparatively, 98.4% of Relay Therapeutics shares are held by institutional investors. 2.5% of Acceleron Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Relay Therapeutics (NASDAQ:RLAY) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Relay Therapeutics and Fate Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Fate Therapeutics04902.69

Relay Therapeutics presently has a consensus target price of $57.40, suggesting a potential upside of 70.68%. Fate Therapeutics has a consensus target price of $108.3125, suggesting a potential upside of 38.88%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Fate Therapeutics.

Valuation and Earnings

This table compares Relay Therapeutics and Fate Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
Fate Therapeutics$10.68 million684.84$-98,150,000.00($1.44)-54.16

Relay Therapeutics has higher earnings, but lower revenue than Fate Therapeutics.

Profitability

This table compares Relay Therapeutics and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
Fate Therapeutics-810.13%-35.51%-25.40%

Institutional & Insider Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Relay Therapeutics beats Fate Therapeutics on 5 of the 9 factors compared between the two stocks.


Relay Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QIAGEN logo
QGEN
QIAGEN
1.5$51.29-0.2%$11.69 billion$1.53 billion63.32Analyst Downgrade
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$115.74-4.0%$8.73 billion$289.59 million-35.50
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.85-1.9%$7.68 billion$73.99 million-48.98
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$77.99-1.3%$7.31 billion$10.68 million-42.39Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$132.23-0.1%$6.43 billion$90.10 million-35.26
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$52.26-1.4%$6.32 billion$26.68 million-23.65
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.42-4.0%$5.63 billion$85.07 million-42.55Insider Selling
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$109.07-1.1%$5.58 billionN/A-47.01
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.13-3.9%$5.52 billion$8.09 million-18.28
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.00-0.2%$4.64 billion$503.70 million32.96
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.82-2.5%$4.62 billionN/A-15.41
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.19-3.7%$4.44 billionN/A-15.72
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$70.23-6.5%$4.39 billion$20,000.00-5.00
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$68.95-3.5%$3.38 billionN/A-39.63
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$70.33-0.1%$3.14 billion$125.57 million-41.13
Revolution Medicines logo
RVMD
Revolution Medicines
1.5$42.67-5.5%$3.13 billion$50.04 million0.00
Vericel logo
VCEL
Vericel
1.1$57.77-3.5%$2.66 billion$117.85 million-5,777,000.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.46-3.3%$2.66 billion$20.53 million-22.68
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.51-3.1%$2.11 billion$31.43 million-5.14
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.88-1.0%$1.94 billionN/A-11.16
bluebird bio logo
BLUE
bluebird bio
1.8$28.16-2.5%$1.89 billion$44.67 million-2.56
NantKwest logo
NK
NantKwest
1.1$32.49-13.0%$1.84 billion$40,000.00-45.76Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.29-6.8%$1.54 billionN/A-46.82News Coverage
Immunovant logo
IMVT
Immunovant
1.8$15.68-1.4%$1.54 billionN/A-12.16
AlloVir logo
ALVR
AlloVir
1.4$23.21-5.2%$1.51 billionN/A0.00
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44-4.6%$1.50 billionN/A0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17-0.0%$1.49 billion$35.23 million-14.18
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66-3.2%$1.41 billionN/A0.00High Trading Volume
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$30.07-1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37-13.0%$1.38 billion$21.22 million-7.79Gap Up
Ocugen logo
OCGN
Ocugen
1.1$6.96-0.7%$1.31 billionN/A-4.70
Translate Bio logo
TBIO
Translate Bio
1.6$17.26-2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77-3.1%$1.15 billionN/A-2.98
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90-0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51-0.6%$1.10 billion$32.16 million-9.67
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22-2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94-6.2%$1.03 billion$20.49 million-12.42
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95-1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59-6.9%$992.65 millionN/A-14.00Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10-5.8%$922.43 million$42.74 million-223.33
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63-0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08-6.9%$887.99 million$250,000.00-7.15
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83-0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34-4.4%$879.60 millionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.